The biotech sector witnessed a see-saw performance in 2024. While the year started on a positive note, much of the gains slowed down in the second half of 2024.
Nonetheless, given the continuous need for innovative medicines, the biotech industry will continue to grab investors’ interest despite the inherent volatility and uncertain macroeconomic environment.
Here, we discuss four biotech stocks that have returned 50% or more year to date and have room for more growth in 2025 on the back of a solid portfolio and a promising pipeline.
This post originally appeared at Zacks.